secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2023-06-07T23:59:59+00:00
Accession:  0001737287-23-000056
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene reports 67% ORR and 58% CR in Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in r/r LBCL
--------------------------------------------------------------------------------

- 67% ORR and 58% CR in CAR T-naive r/r LBCL patients (n=12) treated with Phase 2 regimen at ASCO.
- 5 of 7 complete responders maintained CR at 6 months; median DOR 23.1 months; 3 patients in remission >24 months, longest >31 months.
- No Grade 3+ CRS, ICANS, or GvHD; cytopenias and infections manageable; safety comparable to autologous CAR T.
- Pivotal Phase 2 ALPHA2 trial of ALLO-501A enrolling; expected enrollment completion in first half of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728723000056/0001737287-23-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728723000056/allo-20230603.htm
  HTML page:      https://secwatch.observer/filing/0001737287-23-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer